UY33916A - ?IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS? - Google Patents

?IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS?

Info

Publication number
UY33916A
UY33916A UY0001033916A UY33916A UY33916A UY 33916 A UY33916 A UY 33916A UY 0001033916 A UY0001033916 A UY 0001033916A UY 33916 A UY33916 A UY 33916A UY 33916 A UY33916 A UY 33916A
Authority
UY
Uruguay
Prior art keywords
treatment
triazins
imidazo
neurological disorders
compounds
Prior art date
Application number
UY0001033916A
Other languages
English (en)
Inventor
Patrick Robert Verhoest
Christopher John Helal
Thomas Allen Chappie
John Michael Humphrey
Yang Eddie
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45755439&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33916(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of UY33916A publication Critical patent/UY33916A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a compuestos de Fórmula I,y a sales de los mismos farmacéuticamente aceptables, a procedimientos para la preparación de, a intermedios usados en la preparación de, y composiciones que contienen dichos compuestos y a los usos de dichos compuestos como un procedimiento para el tratamiento, de una enfermedad o afección seleccionada del grupo que consiste en trastornos del sistema nervioso central, trastornos cognitivos, esquizofrenia, demencia y otros trastornos, en un mamífero.
UY0001033916A 2011-02-23 2012-02-22 ?IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS? UY33916A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161445617P 2011-02-23 2011-02-23

Publications (1)

Publication Number Publication Date
UY33916A true UY33916A (es) 2012-09-28

Family

ID=45755439

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033916A UY33916A (es) 2011-02-23 2012-02-22 ?IMIDAZO[5,1-f][1,2,4]TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS?

Country Status (30)

Country Link
US (2) US8598155B2 (es)
EP (1) EP2681218A1 (es)
JP (1) JP5543039B2 (es)
KR (1) KR101548443B1 (es)
CN (1) CN103391941A (es)
AP (1) AP2013007070A0 (es)
AR (1) AR085304A1 (es)
AU (1) AU2012221828C1 (es)
BR (1) BR112013021366A2 (es)
CA (1) CA2825699A1 (es)
CL (1) CL2013002125A1 (es)
CO (1) CO6751271A2 (es)
CR (1) CR20130371A (es)
CU (1) CU20130107A7 (es)
DO (1) DOP2013000194A (es)
EA (1) EA022586B1 (es)
EC (1) ECSP13012892A (es)
GT (1) GT201300206A (es)
IL (1) IL227716A0 (es)
MA (1) MA34922B1 (es)
MX (1) MX2013009684A (es)
NI (1) NI201300071A (es)
PE (1) PE20140236A1 (es)
SG (1) SG192576A1 (es)
TN (1) TN2013000349A1 (es)
TW (1) TWI469983B (es)
UA (1) UA106692C2 (es)
UY (1) UY33916A (es)
WO (1) WO2012114222A1 (es)
ZA (1) ZA201306348B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진
EP2919788A4 (en) 2012-11-14 2016-05-25 Univ Johns Hopkins METHODS AND COMPOSITIONS FOR THE TREATMENT OF SCHIZOPHRENIA
PE20151940A1 (es) * 2013-05-02 2016-01-21 Pfizer Derivados de triazina
US9815796B2 (en) 2013-12-23 2017-11-14 Merck Sharp & Dohme Corp. Pyrimidone carboxamide compounds as PDE2 inhibitors
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
PL3597649T3 (pl) 2014-04-23 2022-04-04 Dart Neuroscience Llc Kompozycje zawierające podstawione związki [1,2,4]triazolo[1,5-a]pirymidyn-7-ylowe jako inhibitory pde2
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
CN107205993B (zh) 2014-12-06 2021-03-09 细胞内治疗公司 有机化合物
WO2016090380A1 (en) 2014-12-06 2016-06-09 Intra-Cellular Therapies, Inc. Organic compounds
CN104525240A (zh) * 2014-12-10 2015-04-22 河北工业大学 硝酸铁作为催化剂在苯与羟胺盐反应一步法制苯胺反应中的应用方法
WO2016103097A1 (en) 2014-12-22 2016-06-30 Pfizer Inc. Antagonists of prostaglandin ep3 receptor
TWI713497B (zh) * 2015-02-26 2020-12-21 南韓商愛思開生物製藥股份有限公司 咪唑并嘧啶及咪唑并三衍生物及包含該衍生物之醫藥組成物
WO2016145614A1 (en) 2015-03-17 2016-09-22 Merck Sharp & Dohme Corp. Triazolyl pyrimidinone compounds as pde2 inhibitors
WO2016154081A1 (en) 2015-03-26 2016-09-29 Merck Sharp & Dohme Corp. Pyrazolyl pyrimidinone compounds as pde2 inhibitors
EP3291817B1 (en) 2015-05-05 2019-10-02 Merck Sharp & Dohme Corp. Heteroaryl-pyrimidinone compounds as pde2 inhibitors
WO2016183741A1 (en) 2015-05-15 2016-11-24 Merck Sharp & Dohme Corp. Pyrimidinone amide compounds as pde2 inhibitors
WO2016191935A1 (en) 2015-05-29 2016-12-08 Merck Sharp & Dohme Corp. 6-alkyl dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016192083A1 (en) 2015-06-04 2016-12-08 Merck Sharp & Dohme Corp. Dihydropyrazolopyrimidinone compounds as pde2 inhibitors
WO2016209749A1 (en) 2015-06-25 2016-12-29 Merck Sharp & Dohme Corp. Substituted pyrazolo/imidazolo bicyclic compounds as pde2 inhibitors
WO2017004134A1 (en) * 2015-06-29 2017-01-05 Nimbus Iris, Inc. Irak inhibitors and uses thereof
WO2017000277A1 (en) 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Substituted triazolo bicycliccompounds as pde2 inhibitors
WO2017000276A1 (en) * 2015-07-01 2017-01-05 Merck Sharp & Dohme Corp. Bicyclic heterocyclic compounds as pde2 inhibitors
AU2016348549B2 (en) * 2015-11-02 2020-07-23 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compound
CN105669680B (zh) * 2016-03-24 2018-02-23 南京药捷安康生物科技有限公司 吡咯并[2,1‑f][1,2,4]三嗪‑4(1H)‑酮衍生物类PDE9A抑制剂
WO2018065288A1 (de) 2016-10-07 2018-04-12 Bayer Cropscience Aktiengesellschaft 2-[2-phenyl-1-(sulfonylmethyl)vinyl]-imidazo[4,5-b]pyridin-derivate und verwandte verbindungen als schädlingsbekämpfungsmittel im pflanzenschutz
MX2019005154A (es) 2016-11-02 2019-06-20 Janssen Pharmaceutica Nv Derivados de [1,2,4]triazol[1,5-a]pirimidina como inhibidores de pde2.
BR112019008163A2 (pt) 2016-11-02 2019-07-09 Janssen Pharmaceutica Nv compostos de [1,2,4]triazolo[1,5-a]pirimidina como inibidores de pde2
US11319321B2 (en) 2016-11-02 2022-05-03 Janssen Pharmaceutica Nv [1,2,4]triazolo[1,5-a]pyrimidine compounds as PDE2 inhibitors
AR113206A1 (es) 2017-01-10 2020-02-19 Bayer Cropscience Ag Derivados heterocíclicos como pesticidas
CN110382485B (zh) 2017-01-10 2022-05-10 拜耳公司 作为害虫防治剂的杂环烯衍生物
EP3713572A1 (en) 2017-11-23 2020-09-30 Oslo University Hospital HF Treatment of tachycardia
CN108640923A (zh) * 2018-07-09 2018-10-12 湖南天地恒制药有限公司 一种托法替布关键中间体的制备方法
EP3870300B1 (en) * 2018-10-23 2024-07-10 Intra-Cellular Therapies, Inc. Imidazo[1,5-a]pyrazine compounds as pde2 inhibitors
US11492362B1 (en) 2022-02-17 2022-11-08 King Abdulaziz University Pyridine derivatives for the treatment of hyperproliferative diseases

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4035893A (en) * 1991-12-17 1993-07-19 Upjohn Company, The 3-substituted imidazo (1,5-a) and imidazo (1,5-a)-triazolo (1,5-c) quinoxalines and quinazolines with cns activity
YU59100A (sh) * 1999-10-11 2003-10-31 Pfizer Inc. Postupak za dobijanje pirazolo (4,3-d) pirimidin-7-ona-3-piridilsulfonil jedinjenja i njihova intermedijera
DE10130167A1 (de) 2001-06-22 2003-01-02 Bayer Ag Imidazotriazine
DE10230605A1 (de) 2002-07-08 2004-01-29 Bayer Ag Substituierte Imidazotriazine
DE10230604A1 (de) * 2002-07-08 2004-01-29 Bayer Ag Heterocyclisch substituierte Imidazotriazine
WO2005041957A1 (en) * 2003-10-29 2005-05-12 Pfizer Products Inc. Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors
MY143225A (en) 2004-04-02 2011-03-31 Osi Pharm Inc 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors
MY139689A (en) 2004-07-20 2009-10-30 Osi Pharm Inc Imidazotriazines as protein kinase inhibitors
DE102004038328A1 (de) * 2004-08-06 2006-03-16 Bayer Healthcare Ag Neue Verwendungen von 2-Phenyl-substituierten Imidazotriazinon-Derivaten
WO2006044687A2 (en) * 2004-10-15 2006-04-27 Takeda San Diego, Inc. Kinase inhibitors
AU2006204451C1 (en) * 2005-01-05 2012-05-24 Takeda Gmbh Triazolophthalazines as PDE2-inhibitors
DE602005022115D1 (de) 2005-01-07 2010-08-12 Pfizer Prod Inc Heteroaromatische chinolinverbindungen und deren verwendung als pde10-inhibitoren
RS51843B (en) 2005-11-17 2012-02-29 Osi Pharmaceuticals Llc. CONDENSED BICYCLIC m TOR INHIBITORS
WO2007087395A2 (en) 2006-01-25 2007-08-02 Osi Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
WO2007106503A2 (en) 2006-03-13 2007-09-20 Osi Pharmaceuticals, Inc. Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors
EP2201840B1 (en) 2006-09-22 2011-11-02 Pharmacyclics, Inc. Inhibitors of Bruton's Tyrosine Kinase
US20090274698A1 (en) 2007-07-06 2009-11-05 Shripad Bhagwat Combination anti-cancer therapy
US7683575B2 (en) 2007-07-18 2010-03-23 Tesla Motors, Inc. Method and apparatus for identifying and disconnecting short-circuited battery cells within a battery pack
US8557814B2 (en) 2008-03-19 2013-10-15 OSI Pharmaceuticals, LLC mTOR inhibitor salt forms
EP2283020B8 (en) 2008-05-19 2012-12-12 OSI Pharmaceuticals, LLC Substituted imidazopyr-and imidazotri-azines
KR20120047256A (ko) 2009-07-09 2012-05-11 오에스아이 파마슈티컬스, 엘엘씨 치환된 3-아미노-5-옥소-4,5-다이하이드로-［1,2,4］트라이아진에 대한 방법
AU2011269788B2 (en) 2010-02-03 2015-12-10 Incyte Holdings Corporation Imidazo[1,2-b][1,2,4]triazines as c-Met inhibitors
KR101548443B1 (ko) * 2011-02-23 2015-08-28 화이자 인코포레이티드 신경 장애의 치료를 위한 이미다조[5,1-f][1,2,4]트라이아진

Also Published As

Publication number Publication date
GT201300206A (es) 2015-02-19
NI201300071A (es) 2014-02-12
SG192576A1 (en) 2013-09-30
CU20130107A7 (es) 2013-09-27
US9200000B2 (en) 2015-12-01
BR112013021366A2 (pt) 2016-09-13
IL227716A0 (en) 2013-09-30
EA201390971A1 (ru) 2014-02-28
KR101548443B1 (ko) 2015-08-28
ZA201306348B (en) 2014-04-30
US20140066622A1 (en) 2014-03-06
CR20130371A (es) 2013-09-18
JP2014506589A (ja) 2014-03-17
PE20140236A1 (es) 2014-03-14
CO6751271A2 (es) 2013-09-16
MX2013009684A (es) 2013-10-28
US8598155B2 (en) 2013-12-03
TWI469983B (zh) 2015-01-21
EP2681218A1 (en) 2014-01-08
TN2013000349A1 (fr) 2015-01-20
KR20130132612A (ko) 2013-12-04
NZ613373A (en) 2015-04-24
AU2012221828B2 (en) 2015-05-28
CA2825699A1 (en) 2012-08-30
CL2013002125A1 (es) 2013-12-20
ECSP13012892A (es) 2013-10-31
US20120214791A1 (en) 2012-08-23
MA34922B1 (fr) 2014-02-01
CN103391941A (zh) 2013-11-13
JP5543039B2 (ja) 2014-07-09
DOP2013000194A (es) 2014-01-31
EA022586B1 (ru) 2016-01-29
AR085304A1 (es) 2013-09-18
UA106692C2 (uk) 2014-09-25
AP2013007070A0 (en) 2013-08-31
WO2012114222A1 (en) 2012-08-30
AU2012221828C1 (en) 2015-10-01
TW201247673A (en) 2012-12-01

Similar Documents

Publication Publication Date Title
CU20130107A7 (es) IMIDAZO[5,1-f][1,2,4] TRIAZINAS PARA EL TRATAMIENTO DE TRASTORNOS NEUROLÓGICOS
ECSP15006871A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
DOP2018000204A (es) Moduladores alostéricos de receptores de acetilcolina nicotínicos
CL2019001626A1 (es) Inhibidores de pequeñas moléculas de la familia jak de quinasas.
GT201300179A (es) Derivados heterociclicos novedosos y su uso en el tratamiento de trastornos neurologicos
CR20140397A (es) Compuestos de oxazolidin-2-ona y usos de los mismos como inhibidores de la pi3ks
AR085219A1 (es) 6-cicloalquil-pirazolopirimidinonas para el tratamiento de trastornos del snc
SG195085A1 (en) Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors
PE20150669A1 (es) Derivados de benzamida para la inhibicion de la actividad de abl1, abl2 y bcr-abl1
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
NI201700055A (es) 2-amino-6-(difluorometil)-5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1
ECSP15012804A (es) Alcoxipirazoles como activadores de guanilato ciclasa soluble
ECSP13012494A (es) Inhibidores de oxadiazol de la producción de leucotrieno.
CU24327B1 (es) Derivados de 1,4-benzotiazepina, útiles para tratar trastornos y enfermedades asociadas con los receptores de rianodina, y las composiciones farmacéuticas que les comprenden
ECSP14013221A (es) Fenil-3-aza-biciclo [3.1.0] hex-3-il-metanonas y su uso como medicamento.
DOP2016000276A (es) 2-AMINO-6-METIL-4,4a,5,6-TETRAHIDROPIRANO[3,4-d][1,3]TIAZIN-8a(8H)-IL-1,3-TIAZOL-4-ILAMIDAS
BR112013019354A2 (pt) derivados de (1,2,4)triazolo[4,3-a]quinoxalina como inibidores de fosfodiesterases
AR123407A1 (es) Un proceso para la fabricación de (6ar,10ar)-7-propil-6,6a,7,8,9,10,10a,11-octahidro-[1,3]dioxolo[4’,5’:5,6]benzo[1,2-g]quinolina y (4ar,10ar)-1-propil-1,2,3,4,4a,5,10,10a-octahidro-benzo[g]quinolina-6,7-diol
CO2017003305A2 (es) Derivados de la amida del ácido 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carboxílico o del 2-[piridin-3-il]-2,3-dihidro-benzo[1,4]dioxin-5-carbonitrilo como inhibidores de aldosterona sintasa
EA201790626A1 (ru) Макроциклические ингибиторы lrrk2-киназы
CO6592112A2 (es) Derivadosde piridina triciclicos, medicamentos que contienen tales compuestos, su uso y proceso para su separaciòn
AR092247A1 (es) INHIBIDORES DE LA b-SECRETASA
CL2018000856A1 (es) Derivados de éter cíclico de pirazolo[1,5-a]pirimidin-3-carboxiamida.
BR112015010512A2 (pt) derivados de carboxamida de 3-aminociclopentano
UY34281A (es) "1,4-diazabiciclo[3.2.2]nonanos como ligandos de receptores nicotínicos neuronales de acetilcolina

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200910